ClinicalTrials.gg
CompletedNCT03374176Updated Sep 16, 2020Results posted

Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes

A Phase 3 interventional study of Amoxicillin 500 mg / Metronidazole 250 mg and Clindamycin 300 mg in Periodontitis, Periodontal Pocket and Diabetes Mellitus, sponsored by Centro Universitario de Tonalá. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-09-16.

Primary conditionPeriodontal PocketRegistry: PeriodontitisReclassifiedWhy we changed it
Registry
Periodontitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Periodontal Pocket
Why
  1. The study's listed conditions name Periodontal Pocket, a narrower term within Periodontitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centro Universitario de Tonalá · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Mar 2014, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Periodontitis is an inflammation of the supporting structures of the teeth, usually caused by specific or groups of microorganisms that results in the progressive destruction of the periodontal ligament and alveolar bone. the objective of periodontitis treatment is to reduce the number of periodontal pathogens. However, there is not an agreement in the use of systemic antibiotics in patients with diabetes. The purpose of the present study was to determine the efficacy of amoxicillin/metronidazole compared to clindamycin during non-surgical treatment of periodontitis in patients with type 2 diabetes mellitus.

Patients and methods In this double-blind, randomized clinical trial, a total of 42 patients with chronic periodontitis and type 2 diabetes were included in a 24-months follow-up. Patients were randomly assigned to treatment with either amoxicillin/metronidazole or clindamycin every for 7 days. Clinical determinations (depth of probing, bleeding at the probe and plaque index) were performed to determine the extent and severity of periodontitis before and after the pharmacological treatment. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant

Read the detailed description

A parallel, randomized, double-blind, active controlled, single center clinical trial was designed to compare the efficacy of two antibiotic therapies with 24-month follow-up. The study protocol was approved by the ethical committee of the Universitary Center of Health Sciences of University of Guadalajara and conducted according to Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent before the initiation of study procedures.

A total of 5 non-study subjects with chronic periodontitis were recruited and used for the calibration exercise. Two designated examiners measured full-mouth probing pockets depths (PPD) for all 5 subjects. On the same day (with a minimum of 15 min separation), the examiner repeated the examination. Upon completion of all measurements, the intra-examiner repeatability for PPD measurement was assessed. The examiner was judged to be reproducible after fulfilling the pre-determined success criteria (the percentage of agreement within 2 mm between repeated measurements had to be at least 70 %). The examiner showed 78.3 % reproducibility.

The sample size was calculated with a 95% confidence level and statistical power of 80 %. A standard deviation of 1.0 mm with an expected difference of 1.0 mm probing pocket depth reduction between treatments. This resulted in a total of 14 patients per arm, however this sample was increased 20% (21 patients per group) to compensate for possible dropouts.

Patient population Criteria for selection Patients of both sexes (aged >18 to 70 years) with a diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions and a history of type 2 diabetes with a HbA1C \< 8 % and a fasting plasma glucose (FPG) \< 180 mg/dL. Patients with aggressive periodontitis, pregnant or lactating females, required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. A history of anti-inflammatory therapy within preceding six months or that had received a course of periodontal treatment within the last 6 months, allergies to penicillin, metronidazole or clindamycin, and were not able to provide consent to participate in the study were also criteria for exclusion.

Intervention Subjects were randomly allocated 1:1 to receive 500 mg amoxicillin + 250 mg metronidazole or 300 mg clindamycin + placebo using a computer that generated a list of random numbers. Subjects were instructed to take the treatment three times a day for 7 days in both groups.

Assessments During these sessions, a case presentation was given to each subject related to the specific features of his/her disease, as well as a supra- and sub-gingival mechanical debridement was performed. A complete periodontal examination was performed, including a full medical and dental history, an intra-oral examination and a full-mouth periodontal probing. A radiographic examination was undertaken using either periapical x-rays or a ortopantomography.

Clinical parameters Clinical parameters were assessed using a North Caroline Periodontal Probe by the calibrated examiner at six sites. Full-mouth plaque scores were recorded by assigning a binary score to each surface (1 for plaque present, 0 for absent) and by calculating the percentage of total tooth surfaces that revealed the presence of plaque detected by the use of tablet. Similarly, a full-mouth percentage bleeding score was calculated after assessing dichotomously the presence of bleeding on probing from the bottom of the pocket when probing with a manual probe with a force of 0.3n. Full-mouth PPD and recession of the gingival margin were recorded at the same time with measurements rounded to the nearest millimeter.

Non-surgical periodontal therapy Periodontal therapy was initiated within 1 month of the baseline screening examination. A standard cycle of periodontal therapy consisting of oral hygiene instructions, supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planning) was performed by two experienced therapists.

Local anesthesia was used as necessary. Patients relied on standard oral hygiene methods as instructed at the commencement of the study.

Post-treatment controls The objectives of the post-treatment appointments were to control and reinforce the oral hygiene habits of each subject, to monitor the early healing events and to report any adverse events or additional medications taken. In addition, the 1-week post-treatment visit served as a compliance control, as subjects were asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the study subjects was documented.

Re-assessment examinations Reassessment visits occurred within a month and a half of the completion of the pharmacological treatment. During these appointments, the examiner recorded any changes in the medical history and repeated clinical periodontal parameters recorded at the basal visit.

Statistical analysis Age, FPG, HbA1C, tooth, and sounding depth were presented in means and standard deviation. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant. All statistical analyses were conducted using SPSS software (IBM Corporation, Armonk, NY, USA) version 21.

02

Conditions studied

  • Periodontitis
  • Periodontal Pocket
  • Diabetes Mellitus

Browse trials for

Keywords

  • periodontitis
  • diabetes mellitus
  • systemic antimicrobials
03

In context

Periodontal Pocket Reclassified

130 studies on the registry are indexed under Periodontal Pocket; 35 are open to participants now.

This study's enrollment of 42 is above the median of 30 across 113 interventional studies indexed under Periodontal Pocket.

Browse Periodontal Pocket studies →

Lead sponsor

Centro Universitario de Tonalá is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Periodontal Pocket, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes
  • Age >18 to 70 years
  • Diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions
  • History of type 2 diabetes
  • \< 8 %
  • Fasting plasma glucose (FPG) \< 180 mg/dL.

Exclusion criteria

Exclusion Criteria:

  • Aggressive periodontitis
  • Pregnant or lactating females,
  • Required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded.
  • A history of anti-inflammatory therapy within preceding six months
  • Had received a course of periodontal treatment within the last 6 months,
  • Allergies to penicillin, metronidazole or clindamycin,
  • Not able to provide consent to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    AMX-MET

    AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules. 1 capsule tid during 7 days.

    Drug: Amoxicillin 500 mg / Metronidazole 250 mg

  • Experimental
    Clindamycin

    Clindamycin Clindamycin 300 mg + placebo. Capsules. 1 capsule tid during 7 days.

    Drug: Clindamycin 300 mg

Interventions

  • DrugAmoxicillin 500 mg / Metronidazole 250 mg

    Drug page: Amoxicillin

    Subjects were instructed to take a capsule three times a day for 7 days

  • Subjects were instructed to take a capsule three times a day for 7 days

06

What researchers measure

Primary outcomes

  1. Probing Depth

    The size of the periodontal pocket

    Time frame: 7 days

Secondary outcomes

  1. Sites With Plaques

    0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome

    Time frame: 7 days

  2. Sites With Bleeding on Probing

    Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

    Time frame: 7 days

  3. Total Count of All Teeth Lost Across All Participants

    The total count of all teeth lost in all participants.

    Time frame: 2 years

07

Results

Posted Jun 23, 2020
Limitations and caveats
The prin- cipal limitation of the present study was the absence of a group with SRP plus placebo. This study design, using a placebo group, could help us to evaluate the efficacy of clindamycin versus SRP alone.

Participant flow

The study was carried out on patients at the Integral Dentistry Clinics of the University Center of Health Sciences of the University of Guadalajara in Jalisco, Mexico. The participants attended for dental care from August 2015 to December 2016.

Participant flow — Overall Study
MilestoneAMX-METClindamycin
Started2121
Completed2121
Not completed00

Outcome measures

PrimaryProbing Depth

The size of the periodontal pocket

Time frame:
7 days
Reported as:
Mean · mm
Probing Depth
mmAMX-METClindamycin
Probing Depth0.44 ± 0.270.50 ± 0.17
Statistical analysis
  • AMX-MET vs Clindamycin · Wilcoxon (Mann-Whitney) · p = <0.05 · Mean difference (net): 0.05
SecondarySites With Plaques

0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome

Time frame:
7 days
Reported as:
Mean · Sites
Sites With Plaques
SitesAMX-METClindamycin
Sites With Plaques17.6 ± 13.315.8 ± 10.0
SecondarySites With Bleeding on Probing

Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame:
7 days
Reported as:
Mean · Sites
Sites With Bleeding on Probing
SitesAMX-METClindamycin
Sites With Bleeding on Probing16.1 ± 11.222.1 ± 12.9
SecondaryTotal Count of All Teeth Lost Across All Participants

The total count of all teeth lost in all participants.

Time frame:
2 years
Reported as:
Number · total count of all teeth lost
Total Count of All Teeth Lost Across All Participants
total count of all teeth lostAMX-METClindamycin
Total Count of All Teeth Lost Across All Participants00

Adverse events

Collected over The adverse events were collected for 10 days. Seven days during the intervention period and 3 days after the final visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMX-MET0/21 (0%)0/21 (0%)0/21 (0%)
Clindamycin0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)AMX-METClindamycinTotal
Mean52.5 ± 8.052.0 ± 10.652.2 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)AMX-METClindamycinTotal
Female101424
Male11718
Fasting Plasma Glucose
Fasting Plasma Glucose(mg/dL)AMX-METClindamycinTotal
Mean134.1 ± 23.3136.3 ± 25.7135.2 ± 24.2
HbA1C
HbA1C(%)AMX-METClindamycinTotal
Mean7.1 ± 0.47.3 ± 0.47.2 ± 0.4
Number of Teeth present in the subjects
Number of Teeth present in the subjects(Teeth)AMX-METClindamycinTotal
Mean25 ± 324 ± 524 ± 4
Probing depth
Probing depth(mm)AMX-METClindamycinTotal
Mean2.4 ± 0.62.6 ± 0.62.5 ± 0.6
Sites with Plaque
Sites with Plaque(Sites)AMX-METClindamycinTotal
Mean40.4 ± 22.940.7 ± 21.940.5 ± 22.1
Bleeding on Probing
Bleeding on Probing(Sites)AMX-METClindamycinTotal
Mean42.4 ± 24.255.6 ± 25.849.0 ± 25.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jul 2016, 28 months.

Results were first posted in Jun 2020, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Dec 15, 2017
StartActual
Mar 2014
Primary completionActual
Jul 2016
CompletionActual
Sep 2017
Results first posted
Jun 23, 2020
Last update
Sep 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03374176
Lead sponsor
Centro Universitario de Tonalá
Responsible party
Arieh Roldán Mercado Sesma (Research professor associate B, Centro Universitario de Tonalá) — Principal investigator
First posted
Dec 15, 2017
Start date
Mar 2014
Primary completion
Jul 2016
Completion
Sep 2017
Results posted
Jun 23, 2020
Last update
Sep 16, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clindamycin

Start the discussion